COPENHAGEN, April 8 (Reuters) - The Novo Nordisk Foundation has refiled an application to the U.S. Federal Trade Commission for approval of a $16.5 billion deal to buy Catalent, a spokesperson said on Monday. (Reporting by Jacob Gronholt-Pedersen, writing by Stine Jacobsen, editing by Anna Ringstrom)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
986.8 DKK | +0.28% | +6.87% | +41.44% |
12:00pm | Added health benefits of Wegovy, Zepbound could attract more men, doctors say | RE |
Jun. 06 | Novo Nordisk braces for Ozempic rivals in China | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
986.7 DKK | +0.27% | +6.87% | 632B | ||
56.39 USD | +0.32% | +4.83% | 10.21B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.44% | 632B | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.81% | 248B | |
-1.96% | 219B | |
+10.84% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk owner refiles U.S. application for approval of Catalent deal